-
Mashup Score: 6Prevalence, Risk Profiles, and National Implications of Nonalcoholic Fatty Liver Disease in Pregnant Individuals - 3 month(s) ago
The prevalence of nonalcoholic fatty liver disease (NAFLD) in women of childbearing age in the United States has been estimated at 9%,1 but there are limited data on prevalence in pregnant people.2 Predominantly retrospective studies have suggested that NAFLD during pregnancy is associated with multiple adverse pregnancy complications, including gestational diabetes, preeclampsia, preterm birth, and postpartum hemorrhage.2–4 Prior studies have been limited primarily by reliance on diagnostic codes to identify women with NAFLD, potentially resulting in under-reporting and misclassification of NAFLD in pregnant women.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0NAFLD Presents Similar Risk for Adverse Outcomes Regardless of BMI - 4 month(s) ago
Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 15Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease – A Population-based Cohort Study - 5 month(s) ago
It has been suggested that patients with nonalcoholic fatty liver disease (NAFLD) might be at increased risk of severe infections, but large-scale data from cohorts with biopsy-proven NAFLD are lacking.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 8NAFLD Familial Risk Score Tops FIB-4 Index for Finding Fibrosis - 5 month(s) ago
A new risk model for nonalcoholic fatty liver disease could offer a simpler and more accurate way of predicting advanced fibrosis in first-degree relatives.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12
Gut bacteria translocate into the liver through a disrupted gut vascular barrier, which is an early and common event in the development of nonalcoholic fatty liver disease (NAFLD). Liver sinusoidal endothelial cells (LSECs) are directly exposed to translocated gut microbiota in portal vein blood. Escherichia coli, a commensal gut bacterium with flagella, is markedly enriched in the gut microbiota of patients with NAFLD. However, the impact of E coli on NAFLD progression and its underlying mechanisms remains unclear.
Source: www.cmghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 3Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study - 6 month(s) ago
It is unclear whether health-related quality of life (HRQoL) is impaired in patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis and how this compares with the general population. We aimed to assess HRQoL in patients with NAFLD in comparison to the general population and any associations of fibrosis severity and metabolic comorbidities with impairments in HRQoL.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Individuals with low birthweight 4 times more likely to develop NAFLD later in life - 7 month(s) ago
Individuals with low birthweight or born small for gestational age were significantly more likely to develop nonalcoholic fatty liver disease later in life, with additionally higher odds for more severe NAFLD, according to data at UEG Week. “While previous research has established the link between birthweight and major diseases, such as cardiovascular disease and metabolic syndrome, the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0EASD 23: Efinopegdutide in NAFLD & Type 2 Diabetes Patients - 7 month(s) ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0
Mazen Noureddin, MD, MHSc discusses results from the phase 2a trial of HU6 and explains its significant impact on liver fat and body weight.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3More Pediatric Patients with NASH, NAFLD are Male, Hispanic than Adult Patient Population - 7 month(s) ago
An analysis of age-stratified fatty liver disease patient demographics show a surprising shift in racial/ethnic and sex trends among children and adolescents.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
Study examines prevalence, risk profiles, and national implications of #NAFLD in pregnant individuals. Want to learn more? Click the link 🔗https://t.co/VzajUPEiSN https://t.co/TpaBufLe7R